SCHEMBL1754944

SCHEMBL1754944

CC(C)(C)OC(=O)NC1CCC(Oc2ccc3cnc(Cl)cc3c2)CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 3/20 0.45
RAF1 P04049 2/20 0.43
CACNB4 O00305 1/20 0.43
CACNA1A O00555 1/20 0.43
CACNA1G O43497 1/20 0.43
CACNG3 O60359 1/20 0.43
CACNA1F O60840 1/20 0.43
CACNA1H O95180 1/20 0.43
CACNB3 P54284 1/20 0.43
CACNA2D1 P54289 1/20 0.43
CACNG7 P62955 1/20 0.43
CACNA1B Q00975 1/20 0.43
CACNA1D Q01668 1/20 0.43
CACNB1 Q02641 1/20 0.43
CACNG1 Q06432 1/20 0.43
CACNB2 Q08289 1/20 0.43
CACNA1S Q13698 1/20 0.43
CACNA1C Q13936 1/20 0.43
CACNA1E Q15878 1/20 0.43
CACNA2D4 Q7Z3S7 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15683845 1.00 EPHX2 (0.45) EPHX2RAF1CACNB4CACNA1ACACNA1G
SCHEMBL13407524 0.84 ABL1 (0.44) EPHX2RAF1CACNB4CACNA1ACACNA1G
SCHEMBL18615436 0.84 EPHX2 (0.53) EPHX2RAF1CACNB4CACNA1ACACNA1G
SCHEMBL30738183 0.82 EPHX2 (0.47) EPHX2RAF1CACNB4CACNA1ACACNA1G
SCHEMBL2334311 0.82 EPHX2 (0.47) EPHX2RAF1CACNB4CACNA1ACACNA1G
SCHEMBL2334308 0.82 EPHX2 (0.47) EPHX2RAF1CACNB4CACNA1ACACNA1G
SCHEMBL2500642 0.81 GPR119 (0.52)
SCHEMBL31165461 0.81 CACNB4 (0.47) EPHX2RAF1CACNB4CACNA1ACACNA1G
SCHEMBL18616057 0.79 CACNB4 (0.50) EPHX2RAF1CACNB4CACNA1ACACNA1G
SCHEMBL20357227 0.79 CACNB4 (0.50) EPHX2RAF1CACNB4CACNA1ACACNA1G

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8710228-B2 Cycloalkylamine substituted isoquinoline derivatives SANOFI (FR) 2014-04-29 US disclosed
EP-2125746-B1 CYCLOALKYLAMINE SUBSTITUTED ISOQUINOLINE DERIVATIVES SANOFI SA (FR) 2012-04-18 EP disclosed
US-20100081671-A1 Cycloalkylamine substituted isoquinoline derivatives SANOFI-AVENTIS (FR) 2010-04-01 US disclosed
WO-2008077554-A1 CYCLOALKYLAMINE SUBSTITUTED ISOQUINOLINE DERIVATIVES SANOFI-AVENTIS (FR) 2008-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100081671-A1 Cycloalkylamine substituted isoquinoline derivatives MYLK2, MYLK, MYLK3 EPHX2 3299/4885RAF1 873/4885CACNB4 1644/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.